BlackRock Health Sciences Opportunities PortfolioSHISX
Type
Mutual fund
Peer group
US equity: Healthcare
Net assets
$6.5B
Expense ratio
1.15%
1-year return
+26.0%
3 years, a year
+10.9%
5 years, a year
+5.5%
Holdings
165
What it aims to do.
The investment objective of BlackRock Health Sciences Opportunities Portfolio (the Fund), a series of BlackRock Funds SM (the Trust), is to provide long-term growth of capital.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co. | 11.34% |
| JNJ Johnson & Johnson | 10.22% |
| ABBV AbbVie Inc. | 4.11% |
| GILD Gilead Sciences Inc. | 3.96% |
| MRK Merck & Co., Inc | 3.55% |
| AMGN Amgen Inc. | 3.50% |
| UNH UnitedHealth Group Inc. | 3.04% |
| ISRG Intuitive Surgical Inc. | 2.46% |
| ABT Abbott Laboratories | 2.43% |
| DHR Danaher Corporation | 2.31% |
More on SHISX.
- SHISX overview
- SHISX holdings
- SHISX risk
- SHISX costs
- SHISX money in and out
- SHISX share classes
- Compare SHISX with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.